122 related articles for article (PubMed ID: 8748431)
1. Predicting response to fluoxetine in geriatric patients with major depression.
Koran LM; Hamilton SH; Hertzman M; Meyers BS; Halaris AE; Tollefson GD; Downs JM; Folks DG; Jeste DV; Lazarus LW
J Clin Psychopharmacol; 1995 Dec; 15(6):421-7. PubMed ID: 8748431
[TBL] [Abstract][Full Text] [Related]
2. Clinical response predictors in a double-blind, placebo-controlled trial of fluoxetine for geriatric major depression. Fluoxetine Collaborative Study Group.
Small GW; Hamilton SH; Bystritsky A; Meyers BS; Nemeroff CB
Int Psychogeriatr; 1995; 7 Suppl():41-53. PubMed ID: 8580391
[TBL] [Abstract][Full Text] [Related]
3. Fluoxetine treatment of depressed patients with comorbid anxiety disorders.
Sonawalla SB; Farabaugh A; Johnson MW; Morray M; Delgado ML; Pingol MG; Rosenbaum JF; Fava M
J Psychopharmacol; 2002 Sep; 16(3):215-9. PubMed ID: 12236627
[TBL] [Abstract][Full Text] [Related]
4. Impact of physical illness on quality of life and antidepressant response in geriatric major depression. Fluoxetine Collaborative Study Group.
Small GW; Birkett M; Meyers BS; Koran LM; Bystritsky A; Nemeroff CB
J Am Geriatr Soc; 1996 Oct; 44(10):1220-5. PubMed ID: 8856002
[TBL] [Abstract][Full Text] [Related]
5. Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group.
Silverstone PH; Ravindran A
J Clin Psychiatry; 1999 Jan; 60(1):22-8. PubMed ID: 10074873
[TBL] [Abstract][Full Text] [Related]
6. A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression.
Rudolph RL; Feiger AD
J Affect Disord; 1999 Dec; 56(2-3):171-81. PubMed ID: 10701474
[TBL] [Abstract][Full Text] [Related]
7. Double-blind comparison of bupropion and fluoxetine in depressed outpatients.
Feighner JP; Gardner EA; Johnston JA; Batey SR; Khayrallah MA; Ascher JA; Lineberry CG
J Clin Psychiatry; 1991 Aug; 52(8):329-35. PubMed ID: 1907963
[TBL] [Abstract][Full Text] [Related]
8. The impact of medical comorbidity on acute treatment in major depressive disorder.
Iosifescu DV; Nierenberg AA; Alpert JE; Smith M; Bitran S; Dording C; Fava M
Am J Psychiatry; 2003 Dec; 160(12):2122-7. PubMed ID: 14638581
[TBL] [Abstract][Full Text] [Related]
9. Analysis of the Hamilton Depression Rating Scale factors from a double-blind, placebo-controlled trial of fluoxetine in geriatric major depression.
Tollefson GD; Holman SL
Int Clin Psychopharmacol; 1993; 8(4):253-9. PubMed ID: 8277144
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of fluoxetine and doxepin in treatment of melancholia in depressed patients.
Sandor P; Baker B; Irvine J; Dorian P; McKessok D; Mendlowitz S
Depress Anxiety; 1998; 7(2):69-72. PubMed ID: 9614594
[TBL] [Abstract][Full Text] [Related]
11. An integrated analysis of olanzapine/fluoxetine combination in clinical trials of treatment-resistant depression.
Trivedi MH; Thase ME; Osuntokun O; Henley DB; Case M; Watson SB; Campbell GM; Corya SA
J Clin Psychiatry; 2009 Mar; 70(3):387-96. PubMed ID: 19284928
[TBL] [Abstract][Full Text] [Related]
12. Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study.
Blier P; Ward HE; Tremblay P; Laberge L; Hébert C; Bergeron R
Am J Psychiatry; 2010 Mar; 167(3):281-8. PubMed ID: 20008946
[TBL] [Abstract][Full Text] [Related]
13. A comparison of nefazodone and fluoxetine on mood and on objective, subjective, and clinician-rated measures of sleep in depressed patients: a double-blind, 8-week clinical trial.
Gillin JC; Rapaport M; Erman MK; Winokur A; Albala BJ
J Clin Psychiatry; 1997 May; 58(5):185-92. PubMed ID: 9184611
[TBL] [Abstract][Full Text] [Related]
14. Hopelessness as a predictor of non-response to fluoxetine in major depressive disorder.
Papakostas GI; Petersen T; Homberger CH; Green CH; Smith J; Alpert JE; Fava M
Ann Clin Psychiatry; 2007; 19(1):5-8. PubMed ID: 17453655
[TBL] [Abstract][Full Text] [Related]
15. Sexual functioning in patients with recurrent major depressive disorder enrolled in the PREVENT study.
Gelenberg AJ; Dunner DL; Rothschild AJ; Pedersen R; Dorries KM; Ninan PT
J Nerv Ment Dis; 2013 Apr; 201(4):266-73. PubMed ID: 23538970
[TBL] [Abstract][Full Text] [Related]
16. Novel Augmentation Strategies in Major Depression.
Martiny K
Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
[TBL] [Abstract][Full Text] [Related]
17. Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder.
Fava M; McCall WV; Krystal A; Wessel T; Rubens R; Caron J; Amato D; Roth T
Biol Psychiatry; 2006 Jun; 59(11):1052-60. PubMed ID: 16581036
[TBL] [Abstract][Full Text] [Related]
18. Fluoxetine versus trazodone: efficacy and activating-sedating effects.
Beasley CM; Dornseif BE; Pultz JA; Bosomworth JC; Sayler ME
J Clin Psychiatry; 1991 Jul; 52(7):294-9. PubMed ID: 2071559
[TBL] [Abstract][Full Text] [Related]
19. Fluoxetine versus amitriptyline in the treatment of major depression: a multicenter trial.
Beasley CM; Sayler ME; Potvin JH
Int Clin Psychopharmacol; 1993; 8(3):143-9. PubMed ID: 8263311
[TBL] [Abstract][Full Text] [Related]
20. Characteristics of fluoxetine versus placebo responders in a randomized trial of geriatric depression.
Ackerman DL; Greenland S; Bystritsky A; Small GW
Psychopharmacol Bull; 1997; 33(4):707-14. PubMed ID: 9493483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
